Clinical Trials Logo

Filter by:
NCT ID: NCT01179048 Completed - Clinical trials for Diabetes Mellitus, Type 2

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

LEADER®
Start date: August 31, 2010
Phase: Phase 3
Study type: Interventional

This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.

NCT ID: NCT01178996 Completed - Chronic Hepatitis C Clinical Trials

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic hepatitis C (CHC) already treated with, and not responding to previous courses of PEGIFN alpha plus RBV combination therapy, in comparison with a concurrent group treated with PEG IFN alpha2a in combination with RBV and placebo.

NCT ID: NCT01178450 Completed - Clinical trials for Secondary Hyperparathyroidism

Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation

Start date: January 2010
Phase: Phase 4
Study type: Interventional

The hypothesis of this study is that subtotal parathyroidectomy using minimally invasive surgery is superior to cinacalcet for the treatment of persistent secondary hyperparathyroidism (HPT) post renal transplant, with minimal morbidity and significantly reduces the cost of treatment post transplant.

NCT ID: NCT01178281 Completed - Clinical trials for Primary Myelofibrosis

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

RESUME
Start date: September 8, 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global study) and in reversing anemia in Chinese with MPN-associated myelofibrosis and severe anemia not receiving RBC-transfusions (China extension study only)

NCT ID: NCT01178073 Completed - Clinical trials for Hypertension, Pulmonary

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

AMBITION
Start date: October 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.

NCT ID: NCT01177930 Completed - Quality of Life Clinical Trials

Evaluation of the Health Related Quality of Life and Disease Prevalence of Children From Spain at 6-8 Years of Age Who Participated in a Qualifying Infant Formula Study at Birth

Start date: October 2009
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the influence of the type of feeding in the first year of life on the behavior and health-related quality of life at 6-8 years of age.

NCT ID: NCT01177904 Completed - Pregnant Women Clinical Trials

Early Progesterone Cessation After in Vitro Fertilization

Start date: January 2009
Phase: N/A
Study type: Interventional

There seems to be a general consensus on the supplementation of progesterone (P4) for luteal phase support (LPS) to all women after in vitro fertilization (IVF) treatment. However, there is no agreement about the precise duration of LPS.

NCT ID: NCT01177397 Completed - Multiple Myeloma Clinical Trials

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Start date: July 20, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dose and tumor type for later-stage clinical trials.

NCT ID: NCT01177098 Completed - Glaucoma Clinical Trials

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Start date: October 2010
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A ophthalmic solution with Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once daily for 12 weeks in patients with glaucoma or ocular hypertension.

NCT ID: NCT01176968 Completed - Clinical trials for Myocardial Infarction

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

REMINDER
Start date: September 2010
Phase: Phase 4
Study type: Interventional

Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.